Why the study?
It was unknown whether a fourth dose of a SARS-CoV-2 mRNA-based vaccine improves anti-SARS-CoV-2 antibody response in solid organ transplant recipients.
Does a fourth dose of a SARS-CoV-2 messenger RNA (mRNA)-based vaccine improve anti-SARS-CoV-2 antibody response in solid organ transplant recipients?
Does a fourth dose of a SARS-CoV-2 messenger RNA (mRNA)-based vaccine improve anti-SARS-CoV-2 antibody response in solid organ transplant recipients?
Answers are grounded in this paper and cite their sources.
Fourth mRNA vaccine dose may boost antibodies in transplant recipients; hypothesis-generating case series requiring prospective confirmation before any practice change.
This case series study assesses whether a fourth dose of a SARS-CoV-2 messenger RNA (mRNA)–based vaccine is associated with improved anti–SARS-CoV-2 antibody response in solid organ transplant recipients in France.
No takes yet. Share an insight, caveat, or question.
Kamar et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: